HighVista Strategies’s Jazz Pharmaceuticals JAZZ Stock Holding History

HighVista Strategies’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,838	Closed	-$2.05M	–	162
2026 Q1	$2.05M	Buy	+10,838	New	+$1.89M	0.57%	58
2019 Q2	–	Sell	-4,700	Closed	-$672K	–	123
2019 Q1	$672K	Buy	4,700 +3,000	+176%	+$391K	0.55%	40
2018 Q4	$211K	Buy	+1,700	New	+$252K	0.18%	99

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

HighVista Strategies's JAZZ Position: Q2 2026 in Review

HighVista Strategies sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 10,838 shares — an estimated $2.05M sold.

HighVista Strategies first reported a position in JAZZ in Q4 2018 and held it in 3 quarters. The position peaked at $2.05M in Q1 2026. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

HighVista Strategies reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HighVista Strategies sold 10,838 Jazz Pharmaceuticals shares in Q2 2026, an estimated $2.05M.
HighVista Strategies first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 3 quarters.
HighVista Strategies's Jazz Pharmaceuticals position peaked at $2.05M in Q1 2026.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.